A study examining the number of visits people made to their GP before being diagnosed with cancer through accident and emergency (A&E) has shown that myeloma patients presenting via this route have the highest number of prior GP visits than any other cancer. Published recently in the British Journal Of General Practice, researchers from the Universities of…
Myeloma UK together with the British Committee for Standards in Haematology (BCSH) and the United Kingdom Myeloma Forum (UKMF) have jointly published new guidelines for the screening and management of the late and long-term consequences of myeloma and its treatments. Published recently in the British Journal of Haematology, the guidelines highlight the key late effects…
A study, funded by Myeloma UK, has discovered a mechanism that may explain how a genetic variant increases the risk of developing myeloma. Published in the latest issue of Nature Communications, researchers at The Institute of Cancer Research, London investigated the functional effects of the most highly associated variant they had identified from a previously conducted…
The results of a reassessment of the nationally approved list of drugs made available through the Cancer Drugs Fund (CDF) have been announced by NHS England. They confirm that Imnovid® (pomalidomide) for relapsed and refractory myeloma patients; Revlimid as a second-line treatment, and Velcade® as treatment for multiply relapsed Velcade-naive patients will remain on the list whereas…
